ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 953

Comparative Symptom Severity of Patients Satisfying Chronic Widespread Pain and Fibromyalgia Criteria

Frederick Wolfe1, Brian Wallitt2, Robert S. Katz3 and Winfried Häuser4, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Washington Hospital Center, Baltimore, MD, 3Rush University Medical Center, Chicago, IL, 4Klinikum Saarbrücken, Saarbrücken, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: fibromyalgia

  • Tweet
  • Email
  • Print
Session Information

Session Title: Fibromyalgia and Soft Tissue Disorders

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chronic widespread pain (CWP) is often used as a surrogate for fibromyalgia in epidemiological research, particularly in Europe and in whiplash-related injuries. This CWP substitution occurred because it was operationally impossible to perform tender point examinations in epidemiological and survey research. CWP is a requirement for fibromyalgia diagnosis when the American College of Rheumatology (ACR) 1990 criteria are used. 20-35% of patients with CWP will also satisfy fibromyalgia criteria. Despite the common use of CWP, it is not clear how closely CWP positive patients resemble those with fibromyalgia, and whether CWP is a valid substitution for fibromyalgia. In this report we determined the relative severity of patients satisfying the CWP and fibromyalgia criteria.

Methods : We studied 6,583 rheumatic disease patients who completed a research questionnaire that contained assessments of criteria and severity variables. Fibromyalgia was diagnosed using the 2010 American College of Rheumatology (ACR) criteria for fibromyalgia, as modified for survey research. Widespread pain used the 1990 ACR definition: pain above and below the waist, on the left and right sides of the body, and involving the axial skeleton. Severity measures included the Polysymptomatic Distress Scale (PSD) and the Symptom Severity (SS) scale from the 2010 criteria. In addition, we employed other standard assessments of severity, including measures of pain, sleep, fatigue and quality of life. We categorized patients as a) without CWP, b) with fibromyalgia, c) with CWP assuming 20% of CWP cases had FM, and d) with CWP assuming 33% of CWP cases had fibromyalgia (Table 1).

Results : Figure 1 shows the relation of both measures to PSD in the overall sample.  X and y lines cross when probability of diagnosis is >= 0.5. This occurs at 9.3 and 13.3 on the PSD scale for CWP and FM, respectively. Table 1, adjusted for age and sex, demonstrates that patients with fibromyalgia have more severe symptoms than those with CWP at 20% and 33% prevalence levels. For the 3 clinical VAS scales, fibromyalgia patients are approximately 30% more severe than those with CWP.

Conclusion: Patients satisfying fibromyalgia criteria have a more severe illness than those with CWP. The use of CWP as a surrogate measure of fibromyalgia substantially underestimates fibromyalgia severity, but still identifies a group of severe patients.

Table 1. Severity status of patients with fibromyalgia or chronic widespread pain

Variable

Not

Widespread pain

Mean (95% C.I.)

FMS

Mean (95% C.I.)

Widespread Pain

At 20% FM Prevalence

Widespread Pain

At 33% FM Prevalence

VAS Pain (0-10)

2.8 (2.7, 2.9)

6.1 (6.0, 6.3)

4.3 (4.2, 4.4)

4.6 (4.5, 4.7)

VAS Fatigue (0-10)

3.2 (3.1, 3.3)

7.0 (6.9, 7.1)

4.4 (4.3, 4.5)

4.8 (4.7, 5.0)

VAS Sleep problem (0-10)

3.1 (3.0, 3.2)

6.5 (6.3, 6.6)

4.3 (4.2, 4.5)

4.7 (4.6, 4.8)

Mood (0-10)

2.4 (2.3, 2.4)

4.1 (4.0, 4.2)

2.9 (2.8, 2.9)

3.1 (3.0, 3.2)

HAQ (0-3)

0.7 (0.6, 0.7)

1.5 (1.4, 1.5)

1.1 (1.0, 1.1)

1.1 (1.1, 1.2)

VAS Pt. Global (0-10)

2.8 (2.8, 2.9)

5.8 (5.7, 5.9)

4.1 (4.0, 4.2)

4.3 (4.2, 4.4)

SS Scale (0-12)

3.3 (3.2, 3.4)

7.7, (7.6, 7.8)

4.3 (4.2, 4.4)

4.9 (4.8, 5.0)

WS Pain Index (0-19)

2.1 (2.0, 2.3)

12.3 (12.1, 12.4)

8.2 (8.0, 8.4)

8.9 (8.7, 9.1)

PSD scale (0-31)

6.0 (5.8, 6.2)

20.6 (20.4, 20.9)

13.5 (13.2, 13.8)

14.7 (14.5, 15.0)

EQ-5D (0-1)

0.80 (0.79, 0.80)

0.56 (0.55, 0.57)

0.7 (0.7, 0.7)

0.7 (0.7, 0.7)

PCS

41.8 (41.4, 42.1)

29.3 (28.9, 29.8)

34.8 (34.3, 35.2)

33.9 (33.6, 34.3)

MCS

50.5 (50.1, 50.9)

39.5 (39.0, 40.0)

47.6 (47.1, 48.2)

46.3 (45.8, 46.8)

VAS QOL (0-100)

71.2 (70.5, 71.9)

52.6 (51.7, 53.5)

63.4 (62.5, 64.3)

61.8 (61.0, 62.7)

wspfib.jpg


Disclosure:

F. Wolfe,
None;

B. Wallitt,
None;

R. S. Katz,
None;

W. Häuser,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-symptom-severity-of-patients-satisfying-chronic-widespread-pain-and-fibromyalgia-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences